Exelixis Inc
EXEL41.415USD
+0.535+1.31%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
11.10BCap. mercado
16.84P/E TTM
Más Datos de Exelixis Inc Compañía
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Información de Exelixis Inc
Símbolo de cotizaciónEXEL
Nombre de la empresaExelixis Inc
Fecha de salida a bolsaApr 11, 2000
Director ejecutivoMorrissey (Michael M)
Número de empleados1147
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 11
Dirección1851 Harbor Bay Parkway
CiudadALAMEDA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94502
Teléfono16508377000
Sitio Webhttps://www.exelixis.com/
Símbolo de cotizaciónEXEL
Fecha de salida a bolsaApr 11, 2000
Director ejecutivoMorrissey (Michael M)
Ejecutivos de Exelixis Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.17M
-4.48%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.17M
-7.87%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President
Executive Vice President
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
220.48K
-14.72%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
159.99K
+6.53%
Dr. Brenda Hefti, J.D., Ph.D.
Dr. Brenda Hefti, J.D., Ph.D.
General Counsel
General Counsel
120.61K
+33.36%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
81.98K
+13.60%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
10.57K
+1285.98%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.17M
-4.48%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.17M
-7.87%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President
Executive Vice President
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
220.48K
-14.72%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
CABOMETYX
517.89M
91.14%
License revenues
49.30M
8.68%
COMETRIQ
2.12M
0.37%
Collaboration services revenues
-1.05M
-0.19%
Por regiónUSD
Nombre
Ganancia
Proporción
U.S
524.77M
92.35%
Europe
37.03M
6.52%
Japan
6.46M
1.14%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
CABOMETYX
517.89M
91.14%
License revenues
49.30M
8.68%
COMETRIQ
2.12M
0.37%
Collaboration services revenues
-1.05M
-0.19%
Estadísticas de accionistas
Actualizado: vie., 21 de nov
Actualizado: vie., 21 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.70%
BlackRock Institutional Trust Company, N.A.
9.33%
Farallon Capital Management, L.L.C.
7.27%
Renaissance Technologies LLC
5.77%
State Street Investment Management (US)
4.15%
Otro
63.79%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.70%
BlackRock Institutional Trust Company, N.A.
9.33%
Farallon Capital Management, L.L.C.
7.27%
Renaissance Technologies LLC
5.77%
State Street Investment Management (US)
4.15%
Otro
63.79%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
43.91%
Investment Advisor/Hedge Fund
30.97%
Hedge Fund
15.65%
Pension Fund
3.02%
Individual Investor
2.18%
Research Firm
2.01%
Sovereign Wealth Fund
1.26%
Bank and Trust
0.61%
Family Office
0.19%
Otro
0.21%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
1065
260.68M
98.50%
--
2025Q3
1092
260.70M
99.86%
-131.97K
2025Q2
1104
260.91M
98.66%
+4.64M
2025Q1
1034
261.04M
99.05%
-11.93M
2024Q4
973
257.78M
94.19%
+2.55M
2024Q3
898
254.99M
92.51%
+5.22M
2024Q2
882
250.15M
93.36%
-9.07M
2024Q1
880
259.43M
91.82%
-18.97M
2023Q4
863
265.17M
90.49%
-5.75M
2023Q3
825
271.59M
91.03%
-8.20M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
27.41M
10.18%
-1.20M
-4.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
25.44M
9.45%
-1.05M
-3.97%
Jun 30, 2025
Farallon Capital Management, L.L.C.
16.04M
5.96%
-2.60M
-13.95%
Jun 30, 2025
Renaissance Technologies LLC
15.82M
5.88%
+995.50K
+6.72%
Jun 30, 2025
State Street Investment Management (US)
11.38M
4.23%
-404.95K
-3.43%
Jun 30, 2025
AQR Capital Management, LLC
7.61M
2.83%
+712.19K
+10.33%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
8.78M
3.26%
+980.50K
+12.58%
Jun 30, 2025
LSV Asset Management
7.82M
2.9%
-340.89K
-4.18%
Jun 30, 2025
Geode Capital Management, L.L.C.
7.45M
2.77%
+28.29K
+0.38%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
5.26M
1.95%
+1.58M
+42.93%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
First Trust NYSE Arca Biotechnology Index Fund
3.41%
iShares Genomics Immunology and Healthcare ETF
3.38%
Tema Oncology ETF
3.13%
ERShares Entrepreneurs ETF
2.68%
Invesco Biotechnology & Genome ETF
2.68%
AAM Sawgrass US Large Cap Quality Growth ETF
2.59%
Alger Russell Innovation ETF
2.12%
State Street SPDR S&P Biotech ETF
2.02%
Inspire Growth ETF
1.92%
Invesco S&P MidCap Quality ETF
1.89%
Ver más
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.41%
iShares Genomics Immunology and Healthcare ETF
Proporción3.38%
Tema Oncology ETF
Proporción3.13%
ERShares Entrepreneurs ETF
Proporción2.68%
Invesco Biotechnology & Genome ETF
Proporción2.68%
AAM Sawgrass US Large Cap Quality Growth ETF
Proporción2.59%
Alger Russell Innovation ETF
Proporción2.12%
State Street SPDR S&P Biotech ETF
Proporción2.02%
Inspire Growth ETF
Proporción1.92%
Invesco S&P MidCap Quality ETF
Proporción1.89%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Exelixis Inc?
Los cinco principales accionistas de Exelixis Inc son:
The Vanguard Group, Inc. posee 27.41M acciones, lo que representa el 10.18% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 25.44M acciones, lo que representa el 9.45% del total de acciones.
Farallon Capital Management, L.L.C. posee 16.04M acciones, lo que representa el 5.96% del total de acciones.
Renaissance Technologies LLC posee 15.82M acciones, lo que representa el 5.88% del total de acciones.
State Street Investment Management (US) posee 11.38M acciones, lo que representa el 4.23% del total de acciones.
The Vanguard Group, Inc. posee 27.41M acciones, lo que representa el 10.18% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 25.44M acciones, lo que representa el 9.45% del total de acciones.
Farallon Capital Management, L.L.C. posee 16.04M acciones, lo que representa el 5.96% del total de acciones.
Renaissance Technologies LLC posee 15.82M acciones, lo que representa el 5.88% del total de acciones.
State Street Investment Management (US) posee 11.38M acciones, lo que representa el 4.23% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Exelixis Inc?
Los tres principales tipos de accionista de Exelixis Inc son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
¿Cuántas instituciones poseen acciones de Exelixis Inc (EXEL)?
A fecha de 2025Q4, 1065 instituciones poseen acciones de Exelixis Inc, con un valor de mercado combinado de aproximadamente 260.68M, lo que representa el 98.50% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -1.36%.
¿Cuál es la mayor fuente de ganancias de Exelixis Inc?
El FY2025Q2, el segmento empresarial CABOMETYX generó la ganancia más alta para Exelixis Inc, ascendiendo a 517.89M y representando el 91.14% de la ganancia total.
